Mitochondrial disorders in NSAIDs-induced small bowel injury

Toshio Watanabe,1,* Tetsuya Tanigawa,1 Yuji Nadatani,1 Koji Otani,1 Hirohisa Machida,1 Hirotoshi Okazaki,1 Hirokazu Yamagami,1 Kenji Watanabe,1 Kazunari Tominaga,1 Yasuhiro Fujiwara1 and Tetsuo Arakawa1

1Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan

(Received 29 June, 2010; Accepted 13 July, 2010; Published online 26 February, 2011)

Recent studies using small bowel endoscopy revealed that non-steroidal anti-inflammatory drugs including low-dose aspirin, can often induce small bowel injury. Non-steroidal anti-inflammatory drugs-induced small bowel mucosal injury involves various factors such as enterobacteria, cytokines, and bile. Experimental studies demonstrate that both mitochondrial disorders and inhibition of cyclooxygenases are required for development of non-steroidal anti-inflammatory drugs-induced small bowel injury. Mitochondrion is an organelle playing a central role in energy production in organisms. Many non-steroidal anti-inflammatory drugs directly cause mitochondrial disorders, which are attributable to uncoupling of oxidative phosphorylation induced by opening of the mega channel called mitochondrial permeability transition pore on the mitochondrial membrane by non-steroidal anti-inflammatory drugs. Bile acids and tumor necrosis factor-α also can open the permeability transition pore. The permeability transition pore opening induces the release of cytochrome c from mitochondrial matrix into the cytosol, which triggers a cascade of events that will lead to cell death. Therefore these mitochondrial disorders may cause disturbance of the mucosal barrier function and elevation of the small bowel permeability, and play particularly important roles in early processes of non-steroidal anti-inflammatory drugs-induced small bowel injury. Although no valid means of preventing or treating non-steroidal anti-inflammatory drugs-induced small bowel injury has been established, advances in mitochondrial studies may bring about innovation in the prevention and treatment of this kind of injury.

Key Words: oxidative phosphorylation, uncoupling, mitochondrial permeability transition, aspirin

It has been known since many years ago that non-steroidal anti-inflammatory drugs (NSAIDs) can injure the small bowel as well as upper gastrointestinal tract. Allison et al.1 reported that among 249 autopsied cases that used NSAIDs, small intestinal injuries were found in 21 cases (8.4%), while among 464 cases that did not use NSAIDs, these injuries were found only in 3 cases (0.6%). However, details of this injurious effect of NSAIDs had remained unclarified in the absence of high accuracy small bowel testing methods. In the 21st century, introduction of new modalities such as capsule endoscopy2 and balloon endoscopy3 began to shed light on this “dark continent”, yielding findings such as the potential of NSAIDs to induce small bowel injury frequently regardless of the length of oral NSAID treatment period.

Furthermore, it has been demonstrated that 40–90% of NSAID users had mucosal defects (erosion, ulcer, etc.) which could lead to bleeding, perforation or stenosis.4–7 Now, close attention is paid to this condition. Although onset of NSAIDs-induced small bowel mucosal injury is considered to involve many factors,8–10 its details remain unclarified. This paper will outline the significance of mitochondrial disorders during onset of NSAIDs-induced small bowel mucosal injury.

Mechanism for NSAIDs-Induced Small Bowel Mucosal Injury

NSAIDs, including low-dose aspirin, can induce diverse kinds of mucosal injury such as redness, erosion and ulcer (Fig. 1), affecting the entire small bowel. A mechanism of primary importance for onset of such injury is inhibition of cyclooxygenase (COX) by NSAIDs and collapse of the mucosal defensive system due to reduction of prostaglandin (PG) level following COX inhibition.11 Tanaka et al.10 demonstrated that NSAIDs can induce small intestinal damage when both COX-1 and COX-2 are inhibited. Other than this mechanism, COX-independent topical effect of NSAIDs on small bowel epithelium is considered to play an important role in early processes of injury.12 This direct activity involves effects on mitochondria. That is, NSAIDs can

Fig. 1. NSAIDs-induced small bowel injury. A, B: Capsule endoscope pictures (low-dose aspirin-induced small bowel injury). C, D: Double-balloon endoscope pictures (sulindac-induced small bowel ulcer). A: redness (arrow), B, C, D: ulcer.

*To whom correspondence should be addressed.
E-mail: watanabet@med.osaka-cu.ac.jp

©2011 JCBN

doi: 10.3164/jcbn.10-73

J. Clin. Biochem. Nutr. | March 2011 | vol. 48 | no. 2 | 117–121
injure epithelial cell mitochondrial function, inducing compromised tight junction function, apoptosis, and necrosis.

As a result of such initial disorders, permeability across the small bowel mucosa increases, facilitating invasion of small bowel by luminal injury factors such as enterobacteria and bile. Gram-negative bacteria having invaded the small bowel mucosa activate toll-like receptor 4, a receptor for lipopoly-saccharide, and induce excessive expression of cytokines such as tumor necrosis factor-α through activation of the transcription factors nuclear factor kappa B, leading to neutrophil infiltration. Eventually, the small bowel which has weakened due to PG deficiency cannot suppress stimulation by various injury factors, possibly leading to formation of macroscopic ulcers. As described above, injury of mitochondria by NSAIDs is a key event which can induce a series of inflammatory reactions.

Mitochondrial Structure and Function

Mitochondrion is an organelle playing a central role in energy production in organisms. There are about 100–2,000 mitochondria in each cell. Structurally, the mitochondrion is surrounded by double membranes (outer and inner membranes), and the inner membrane partitions the central matrix from the intermembranous space (the space between inner and outer membranes). The inner membrane of the mitochondrion has numerous folds called “cristae”.

The mitochondrion takes up pyruvic acid, fatty acid, oxygen, adenosine diphosphate (ADP) and phosphoric acid from the surrounding cytoplasm. Within the mitochondrial matrix, pyruvic acid and fatty acid are converted into acetyl CoA. Acetyl CoA then enters the citric acid cycle and is degraded into nicotinamide adenine dinucleotide (NADH) and carbon dioxide.

NADH is subsequently transferred into the inner membrane, where it is converted into NAD, while donating electron to the electron transport chain composed of three respiration enzyme complexes (NADH dehydrogenase complex, cytochrome complex and cytochrome oxidase complex). The electron transport chain releases proton (H⁺) from the matrix to the intermembranous space. As a result, there arises a pH and potential gradient between the intermembranous space and the matrix. The energy derived from this gradient is utilized by adenosine triphosphate (ATP) synthetase to phosphorylate ADP and to synthesize ATP (oxidative phosphorylation). The electron transport chain is coupled to oxidative phosphorylation. Uncoupling agents, which inhibit this series of reactions, suppress the formation of ATP and induce cell death such as apoptosis and necrosis.

NSAIDs-Induced Small Bowel Injury and Mitochondrial Disorders

Somasundaram et al. observed the small bowel epithelium following oral indomethacin treatment under an electron microscope and reported morphological changes of the mitochondrion in early processes of small bowel ulceration. They found mitochondrial vacuolation 1 h after indomethacin treatment and mitochondrial swelling and loss of cristae at 2 h. Similar morphological changes were noted also after treatment with dinitrophenol (an uncoupling agent).

In a study in vitro, NSAIDs such as indomethacin, aspirin, naproxen, and piroxicam uncoupled oxidative phosphorylation of isolated rat liver mitochondria in micromolar and NSAIDs at higher concentrations inhibited respiration in coupled mitochondria, suggesting that the changes in mitochondria observed soon after indomethacin treatment are attributable to its activity to uncouple oxidative phosphorylation and/or inhibit electron transport. The above-mentioned morphological changes of mitochondria were reproduced also following non-oral treatment with indomethacin, but they were absent in animals with ligated bile duct. Aspirin exerted uncoupling activity in vitro but did not induce morphological changes of mitochondria in epithelial cells of the small intestine or small bowel ulceration when administered orally.

When aspirin was administered directly into the small bowel, severe mucosal injury was induced in the area distal to the site of administration. Considering that aspirin is immediately absorbed in the stomach and duodenum without entering the enterohepatic circulation and that indomethacin does not induce ulcers in the bile duct-ligated rats, these results strongly suggest that mitochondrial disorders through the uncoupling of oxidative phosphorylation and/or inhibition of respiration by NSAIDs are indispensable for onset of small bowel ulcers, and it seems likely that such topical effect of NSAIDs on small bowel epithelium is dependent on local drug concentration (concentration within the small bowel) and frequency of exposure to the drug. Other studies also demonstrated importance of mitochondrial disorders by NSAIDs on their intestinal toxicity.

As described above, aspirin has been believed to be less harmful to the small intestine for a long time. However, in 2007, Leung et al. reported a case of small intestinal ulcers in a patient taking low-dose aspirin. So we evaluated ulcerogenicity of aspirin to the small intestine. Capsule endoscopy identified red spots and mucosal breaks (erosions/ulcers) in 100% (11/11) and 90.9% (10/11) of patients who taking low-dose enteric-coated aspirin, respectively. One reason for this very high incidence of injuries by low-dose enteric coated aspirin seems to be intensification of mitochondrial disorders due to exposure of the small bowel mucosa to high concentrations of aspirin dissolved within the small bowel. Further studies including evaluation of the intestinal toxicity of buffered aspirin are needed to support the hypothesis that the enteric-coated formulation of aspirin might be a principal cause of the damage.

Somasundaram et al. conducted a detailed study on the role of mitochondrial disorders in NSAIDs-induced small bowel mucosal injury. They demonstrated: (1) uncombined treatment with dinitrophenol elevated the permeability across small bowel mucosa and induced relatively mild neutrophil infiltration, although it did not induce ulceration; (2) non-oral treatment with aspirin reduced the PG level in small bowel mucosa, but did

| Drugs and administration route | COX inhibition | Mitochondrial disorders | Ulceration |
|-------------------------------|---------------|-------------------------|------------|
| Oral treatment with indomethacin | +             | +                       | +          |
| Non-oral treatment with indomethacin | +             | +                       | +          |
| Non-oral indomethacin + bile duct ligation | +             | +                       | +          |
| Oral treatment with aspirin | +             | –                       | –          |
| Aspirin administration into small bowel | +             | +                       | +          |
| Dinitrophenol administration into small bowel | –             | +                       | –          |
| Non-oral aspirin + dinitrophenol administration into small bowel | +             | +                       | +          |

COX, cyclooxygenase.

Table 1. Effects of drug administration routes on onset of small bowel ulcer

doi: 10.3164/jcbn.10-73
©2011 JCBN
not affect small bowel permeability or induce ulceration; and (3) treatment with dinitrophenol in combination with non-oral aspirin resulted ulceration. These findings suggest that mitochondrial disorders due to uncoupling of oxidative phosphorylation disturb the mucosal barrier function and elevate the small bowel permeability, but that PG deficiency through COX inhibition is additionally needed for ulceration to occur (Table 1).

Mitochondrial Permeability Transition and NSAIDs

Mitochondrial permeability transition (elevation of permeability across the mitochondrial membrane) is a phenomenon of sharp elevation in the permeability of substances (below 1,500 Da in molecular weight) across the mitochondrial membrane.\(^\text{(24)}\) This phenomenon is initiated by opening of the mega-channel called mitochondrial permeability transition pore (PTP; composed of voltage-dependent anion channel (porin), adenine nucleotide translocase, cyclophilin D, etc.) on the mitochondrial membrane (Fig. 2). When the PTP is opened, low-molecularweight substances can freely penetrate the mitochondrial matrix, carrying along with them water and resulting in mitochondrial swelling and the release of cytochrome c into the cytosol. Cytochrome c release triggers a cascade of events that will lead to either apoptosis (in ATP-replete cells) or necrosis (in ATP-depleted cells).\(^\text{(25–27)}\)

As described above, NSAIDs have uncoupling activity. This activity is considered to be attributable, at least partially, to induction of PTP. Masubuchi et al.\(^\text{(28)}\) reported that diclofenac-induced mitochondrial swelling and depolarization of membranes, resulting in release of Ca\(^{2+}\) (accumulated within mitochondria) and suppression of ATP formation by cells. They added that these effects of diclofenac were suppressed by cyclosporine A (a PTP inhibitor). Salicylic acid, an active metabolite of aspirin, was shown to open PTP in kidney cells by Al-Nasser et al.\(^\text{(29)}\) and in liver cells by Trost et al.\(^\text{(30)}\) On the basis of the findings from these studies, it is now considered that the cytotoxic activity of NSAIDs is partially explained by their effect on PTP. So far as NSAIDs-induced small bowel mucosal injury is concerned, opening of PTP seems to be involved in elevation of the intestinal permeability, epithelial cell apoptosis, and necrosis. The mechanism by NSAIDs cause mitochondrial dysfunction is still unclear. Lal et al.\(^\text{(31)}\) reported that several NSAIDs including ketorolac and diclofenac open PTP only under conditions of oxidative stress and in a Ca\(^{2+}\)-dependent fashion.

Mitochondrial Disorders Due to Other Factors

Bile plays an important role in the mechanism for NSAIDs-induced small bowel mucosal injury.\(^\text{(14,19)}\) Bile acids such as chenodeoxycholate are known to open PTP.\(^\text{(32)}\) Furthermore, many apoptotic signaling molecules act as PTP inducers, and these include lipid mediators like ceramides and arachidonic acid.\(^\text{(33,34)}\) The latter is particularly interesting in the context of Ca\(^{2+}\)-dependent cell death. Indeed, it has been shown that arachidonic acid-selective, Ca\(^{2+}\)-dependent phospholipase A2 is essential for the cytotoxic action of tumor necrosis factor-α,\(^\text{(35)}\) which triggers PTP opening through activation of phospholipid hydrolysis and that arachidonic acid signals apoptosis through a mitochondrial effect that can be amplified by inhibition of COX.\(^\text{(33)}\) It seems therefore likely that various factors other than NSAIDs are also involved in mitochondrial disorders which arise during the course of small bowel ulceration.

Rebamipide, an anti-ulcer agent,\(^\text{(40–42)}\) suppressed indomethacin-induced mitochondrial permeability transition in gastric epithelial cells.\(^\text{(43)}\) Recently, it was reported that this drug was useful in preventing diclofenac-induced small bowel injury.\(^\text{(44)}\) This finding seems to be significant when arguing about the features of NSAIDs-induced small bowel mucosal injury and drugs useful in preventing or treating such injury.

Conclusions

Close attention has recently been paid to small bowel diseases

---

**Fig. 2. Structure and function of mitochondrial permeability transition pore.** HK, hexokinase; BR, benzodiazepine receptor; CK, creatine kinase; ANT, adenine nucleotide translocase; VDAC, voltage-dependent anion channel; CypD, cyclophilin D, OM, outer membrane; IM, inner membrane.
in the field of gastroenterology. NSAIDs-induced small bowel injury is a representative of such small bowel diseases. The mechanism for NSAIDs-induced small bowel injury involves enterobacteria, bile, intestinal hypermotility, cytokines, neutrophils, etc. As described in this paper, mitochondrial disorders in small bowel epithelial cells also play an important role in early processes of this kind of injury. Although no valid means of preventing or treating NSAIDs-induced small bowel injury has been established, advances in mitochondrial studies may bring about innovation in the prevention and treatment of this kind of injury.

References

1 Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of nonsteroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749–754.
2 Iddan G, Meron G, Gluhovsky A, Swain P. Wireless capsule endoscopy. Nature 2000; 405: 417.
3 Yamamoto H, Sekine Y, Sato Y, and et al. Total enteroscopy with a non-surgical steerable double-ballon method. Gastrointest Endosc 2001; 53: 216–220.
4 Goldstein JL, Eisen GM, Lewis B, Granleigh IM, Zlotnick S, Fort JG. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133–141.
5 Watanabe T, Sugimori S, Kameda N, and et al. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study. Clin Gastroenterol Hepatol 2008; 6: 1279–1282.
6 Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172–1178.
7 Sugimori S, Watanabe T, Tabuchi M, and et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. Digestion 2008; 78: 208–213.
8 Higuchi K, Umegaki E, Watanabe T, and et al. Present status and strategy of NSAIDs-induced small bowel injury. J Gastroenterol 2009; 44: 879–888.
9 Higuchi K, Yoda Y, Amagase K, and et al. Prevention of NSAID-induced small intestinal mucosal injury: prophylactic potential of lansoprazole. J Clin Biochem Nutr 2009; 45: 125–130.
10 Tanaka A, Hase S, Miyazawa T, Ohno R, Takeuchi K. Role of cyclooxygenase (COX)-1 and COX-2 inhibition in nonsteroidal anti-inflammatory drug-induced intestinal damage in rats: relation to various pathogenic events. J Pharmacol Exp Ther 2002; 303: 1248–1254.
11 Takeuchi K, Tanaka A, Kato S, Amagase K, Satoh H. Roles of COX inhibition in pathogenesis of NSAID-induced small intestinal damage. Clin Chim Acta 2010; 411: 459–466.
12 Somasundaram S, Hayllar H, Rafi S, Wrigglesworth JM, Macpherson AJ, Bjarnason I. The biochemical basis of non-steroidal anti-inflammatory drug-induced damage to the gastrointestinal tract: a review and a hypothesis. Scand J Gastroenterol 1995; 30: 289–299.
13 Robert A, Asano T. Resistance of germfree rats to indomethacin-induced intestinal lesions. Prostaglandins 1977; 14: 333–341.
14 Jacob M, Foster R, Sigh Thorsson G, Simpson R, Bjarnason I. Role of bile in pathogenesis of indomethacin-induced enteropathy. Arch Toxicol 2007; 81: 291–298.
15 Watanabe T, Higuchi K, Kobata A, and et al. Non-steroidal anti-inflammatory drug-induced small intestinal damage is Toll-like receptor 4 dependent. Gut 2008; 57: 181–187.
16 Watanabe T, Nishio H, Tanigawa T, and et al. Probiotic Lactobacillus casei strain Shirota prevents indomethacin-induced small intestinal injury: involvement of lactic acid. Am J Physiol Gastrointest Liver Physiol 2009; 297: G506–G513.
17 Zick M, Rabl R, Reichert AS. Cristae formation-linking ultrastructure and function of mitochondria. Biochim Biophys Acta 2017; 1793: 5–19.
18 Sherratt HS. Mitochondria: structure and function. Rev Neurol (Paris) 1991; 47: 417–430.
19 Somasundaram S, Rafi S, Hayllar J, and et al. Mitochondrial damage: a possible mechanism of the “topical” phase of NSAID induced injury to the rat intestine. Gut 1997; 41: 344–353.
20 Ohe K, Hayashi K, Shirakawa T, Yamada K, Kawasaki T, Miyoshi A. Aspirin- and taurocholate-induced metabolic damage in mammalian gastric mucosa in vitro. Am J Physiol 1980; 239: G457–G462.
21 Jorgensen TG, Weiss-Fogh US, Nielsen HL, Olesen HP, Salicylate- and aspirin-induced uncoupling of oxidative phosphorylation in mitochondria isolated from the mucosal membrane of the stomach. Scand J Clin Lab Invest 1976; 36: 649–654.
22 Leung WK, Bjarnason I, Wong VW, Sung JJ, Chan FK. Small bowel enteropathy associated with chronic low-dose aspirin therapy. Lancet 2007; 369: 614.
23 Somasundaram S, SighThorsson G, Simpson R, and et al. Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat. Aliment Pharmacol Ther 2000; 14: 639–650.
24 Javadov S, Karmazyn M. Mitochondrial permeability transition pore opening as an endpoint to initiate cell death and as a putative target for cardioprotection. Cell Physiol Biochem 2007; 20: 1–22.
25 O’Rourke B. Pathophysiological and protective roles of mitochondrial ion channels. J Physiol 2000; 529 Pt 1: 23–36.
26 Scatena R, Bottoli P, Botta G, Martorana GE, Giardina B. The role of mitochondrial in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007; 293: C12–C21.
27 Omatsu T, Naito Y, Handa O, and et al. Reactive oxygen species–quenching and anti-apoptotic effect of polaprezinc on indomethacin-induced small intestinal epithelial cell injury. J Gastroenterol 2010; 45: 692–702.
28 Masubuchi Y, Nakayama S, Horie T. Role of mitochondrial permeability transition in diclofenac-induced hepatocyte injury in rats. Hepatology 2002; 35: 544–551.
29 Al-Nasser IA. Salicylate-induced kidney mitochondrial permeability transition is prevented by cyclosporin A. Toxicol Lett 1999; 105: 1–8.
30 Trost LC, Lemasters JJ. Role of the mitochondrial permeability transition in salicylate toxicity to cultured rat hepatocytes: implications for the pathogenesis of Reye’s syndrome. Toxicol Appl Pharmacol 1997; 147: 431–441.
31 Lal N, Kumar J, Erdahl WE, and et al. Differential effects of non-steroidal anti-inflammatory drugs on mitochondrial dysfunction during oxidative stress. Arch Biochem Biophys 2009; 490: 1–8.
32 Rolo AP, Oliveira PJ, Moreno AJ, Palmeira CM. Chenodeoxycholate is a potent inducer of the permeability transition pore in rat liver mitochondria. Biosci Rep 2001; 21: 73–80.
33 Gugliucci A, Ranzato L, Scorrano L, and et al. Mitochondria are direct targets of the lipooxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxygenase inhibitors. J Biol Chem 2002; 277: 31789–31795.
34 Scorrano L, Penzo D, Petronilli V, Pagano F, Bernardi P. Arachidonic acid causes cell death through the mitochondrial permeability transition. Implications for tumor necrosis factor-alpha apoptotic signaling. J Biol Chem 2001; 276: 12035–12040.
35 Hayakawa M, Ishida N, Takeuchi K, and et al. Arachidonic acid-selective cyclooxygenase P2A is crucial in the cytotoxic action of tumor necrosis factor. J Biol Chem 1993; 268: 11290–11295.
36 Bradham CA, Qian T, Streetz K, Trautwein C, Brenner DA, Lemasters JJ. The mitochondrial permeability transition is required for tumor necrosis factor-alpha-mediated apoptosis and cytochrome c release. Mol Cell Biol 1998; 18: 6353–6364.
37 Pastornik JG, Simbula G, Yamamoto K, Glascott PA, Jr., Rothman RJ, Farber JL. The cytotoxicity of tumor necrosis factor depends on induction of the

Abbreviations

ADP adenosine diphosphate
ATP adenosine triphosphate
COX cyclooxygenase
NADH nicotinamide adenine dinucleotide
NSAIDs non-steroidal anti-inflammatory drugs
PG prostaglandin
PTP permeability transition pore

doi: 10.3164/jcbn.10-73
©2011 JCBN
mitochondrial permeability transition. *J Biol Chem* 1996; **271**: 29792–29798.

38 Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying non-steroidal antiinflammatory drug-mediated apoptosis. *Proc Natl Acad Sci USA* 1996; **93**: 681–686.

39 Cao Y, Pearson AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. *Proc Natl Acad Sci USA* 2000; **97**: 11280–11285.

40 Watanabe T, Higuchi K, Hamaguchi M, and *et al.* Rebamipide prevents delay of acetic acid-induced gastric ulcer healing caused by *Helicobacter pylori* infection in Mongolian gerbils. *Dig Dis Sci* 2002; **47**: 1582–1589.

41 Watanabe T, Higuchi K, Taira K, and *et al.* Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. *Dig Dis Sci* 2005; **50** Suppl 1: S63–S69.

42 Ono S, Kato M, Imai A, and *et al.* Preliminary trial of rebamipide for prevention of low-dose aspirin-induced gastric injury in healthy subjects: a randomized, double-blind, placebo-controlled, cross-over study. *J Clin Biochem Nutr* 2009; **45**: 248–253.

43 Nagano Y, Matsui H, Muramatsu M, and *et al.* Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-I cells. *Dig Dis Sci* 2005; **50** Suppl 1: S76–S83.

44 Niwa Y, Nakamura M, Ohmiya N, and *et al.* Efficacy of rebamipide for diclofenac-induced small-intestinal mucosal injuries in healthy subjects: a prospective, randomized, double-blinded, placebo-controlled, cross-over study. *J Gastroenterol* 2008; **43**: 270–276.